Recently, we were able to show that genetic single Stabilin deficiency and anti-Stabilin antibody therapy in different atherosclerosis-prone mouse models ameliorate atherosclerosis, likely through altered immune cell activation mediated by a plasma proteome switch including TGFBi and POSTN [8]. Here, TGFBI is linked to atherosclerosis.